JP2013241355A - Tie2 activator, angiogenesis inhibitor, blood vessel maturing agent, blood vessel normalizing agent, blood vessel stabilizer and pharmaceutical composition - Google Patents
Tie2 activator, angiogenesis inhibitor, blood vessel maturing agent, blood vessel normalizing agent, blood vessel stabilizer and pharmaceutical composition Download PDFInfo
- Publication number
- JP2013241355A JP2013241355A JP2012114785A JP2012114785A JP2013241355A JP 2013241355 A JP2013241355 A JP 2013241355A JP 2012114785 A JP2012114785 A JP 2012114785A JP 2012114785 A JP2012114785 A JP 2012114785A JP 2013241355 A JP2013241355 A JP 2013241355A
- Authority
- JP
- Japan
- Prior art keywords
- blood vessel
- vascular
- agent
- tie2
- action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 74
- 101100481410 Mus musculus Tek gene Proteins 0.000 title claims abstract description 67
- 101100481408 Danio rerio tie2 gene Proteins 0.000 title claims abstract description 66
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 title claims abstract description 26
- 239000004037 angiogenesis inhibitor Substances 0.000 title claims abstract description 26
- 229940121369 angiogenesis inhibitor Drugs 0.000 title claims abstract description 26
- 239000012190 activator Substances 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 210000004204 blood vessel Anatomy 0.000 title abstract description 86
- 239000003381 stabilizer Substances 0.000 title abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 230000002792 vascular Effects 0.000 claims description 84
- 230000035800 maturation Effects 0.000 claims description 35
- 238000010606 normalization Methods 0.000 claims description 25
- 230000006641 stabilisation Effects 0.000 claims description 25
- 238000011105 stabilization Methods 0.000 claims description 25
- 230000009471 action Effects 0.000 abstract description 48
- 230000033115 angiogenesis Effects 0.000 abstract description 24
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 241000214021 Astragalus complanatus Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 description 27
- 210000003556 vascular endothelial cell Anatomy 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000000605 extraction Methods 0.000 description 18
- 239000000843 powder Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- -1 aliphatic ketones Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 231100000216 vascular lesion Toxicity 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000009088 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 240000000759 Lepidium meyenii Species 0.000 description 2
- 235000000421 Lepidium meyenii Nutrition 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 235000001466 Ribes nigrum Nutrition 0.000 description 2
- 241001312569 Ribes nigrum Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 235000012902 lepidium meyenii Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 229940029982 garlic powder Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 235000020729 noni extract Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤及び血管の安定化剤、並びに医薬品組成物に関する。 The present invention relates to a Tie2 activator, an angiogenesis inhibitor, a vascular maturation agent, a vascular normalizer and a vascular stabilizer, and a pharmaceutical composition.
血管は、血管内皮細胞と血管壁細胞(血管平滑筋細胞やペリサイト)とが、細胞外マトリックスを介して、間接的に又は直接的に接着する構造を有しており、酸素及び栄養素を生体組織に供給して生体組織から老廃物を除去する機能を有する。 A blood vessel has a structure in which vascular endothelial cells and vascular wall cells (vascular smooth muscle cells and pericytes) are indirectly or directly bonded via an extracellular matrix, and oxygen and nutrients are absorbed by living bodies. It has a function of supplying waste tissue to remove waste from living tissue.
一般に、血管の形成は、新たに血管が形成される血管発生(vasculogenesis)と、形成された既存の血管が伸長して分岐することにより、新たな血管のネットワークが形成される血管新生(angiogenesis)との2段階に分けられる。前者は、血管内皮増殖因子(VEGF)が作用し、脈管形成とよばれる血管の初期発生からその後の血管新生に至るまで非常に広い範囲の血管形成に関与するものであり、後者は、アンジオポエチン(Ang)が作用し、血管内皮細胞と血管壁細胞との接着の制御、血管の構造的安定化に関与するものである。 In general, the formation of blood vessels includes angiogenesis in which new blood vessels are formed, and angiogenesis in which new blood vessels are formed by the elongation and branching of existing blood vessels. And divided into two stages. In the former, vascular endothelial growth factor (VEGF) acts and is involved in a very wide range of angiogenesis from the initial development of blood vessels called angiogenesis to the subsequent angiogenesis, and the latter is angiopoietin. (Ang) acts and participates in the control of adhesion between vascular endothelial cells and vascular wall cells and the structural stabilization of blood vessels.
血管は通常の酸素状況では、血管内皮細胞とその周囲を裏打ちする血管壁細胞とが強固に接着しており、血管構造が安定に保たれているが、組織で低酸素が生じると血管壁細胞が血管内皮細胞から脱離し、無秩序な血管が増生することがある。このような現象は、血管新生と呼ばれており、腫瘍、慢性関節リウマチ、糖尿病網膜症、高脂血症、高血圧などの血管病変を主体とした疾患において、しばしば観察される。 Under normal oxygen conditions, vascular endothelial cells and the vascular wall cells lining them are firmly adhered to each other, and the vascular structure is kept stable. However, when hypoxia occurs in tissues, vascular wall cells May detach from vascular endothelial cells and increase the growth of disordered blood vessels. Such a phenomenon is called angiogenesis and is often observed in diseases mainly consisting of vascular lesions such as tumors, rheumatoid arthritis, diabetic retinopathy, hyperlipidemia, and hypertension.
これらの血管新生は、血管内皮細胞に発現する受容体型チロシンキナーゼTie2(Tyrosine kinase with Ig and EGF homology domain2)を活性化させることにより、抑制されることが知られている(例えば、特許文献1参照)。血管狭小化あるいは血管拡大化の抑制が原因となって生じる虚血性疾患は、Tie2の活性化により、血管腔が拡大化されることが報告されている(例えば、非特許文献1参照)。また、Tie2の活性化により、血管内皮細胞の細胞死を抑制することが報告されている(例えば、非特許文献2参照)。 These angiogenesis are known to be suppressed by activating the receptor tyrosine kinase Tie2 (Tyrosine kinase with Ig and EGF homology domain 2) expressed in vascular endothelial cells (see, for example, Patent Document 1). ). It has been reported that an ischemic disease caused by suppression of narrowing of a blood vessel or expansion of a blood vessel results in enlargement of a blood vessel cavity due to activation of Tie2 (for example, see Non-Patent Document 1). In addition, it has been reported that Tie2 activation suppresses cell death of vascular endothelial cells (see, for example, Non-Patent Document 2).
このように、Tie2の活性化は、血管新生を抑制することができるだけでなく、血管を成熟化、正常化、及び安定化させることも知られている。
例えば、血管再生医療では、Tie2の活性化により、血管における血管内皮細胞と血管壁細胞との接着を誘導して、血管を成熟化させることが知られている。
例えば、腫瘍、糖尿病性網膜症等で観察される血管壁細胞が血管内皮細胞に接着しないことにより無秩序な血管が増生する疾患では、Tie2の活性化により、血管壁細胞を内皮細胞に接着させ、血管を正常化させることが知られている。
例えば、種々の細胞内外の血管構造を破綻させる環境因子に対しては、Tie2の活性化により、血管の不安定化を抑制し、血管を安定化させることが知られている。
Thus, activation of Tie2 is known not only to suppress angiogenesis but also to maturate, normalize, and stabilize blood vessels.
For example, in vascular regenerative medicine, it is known that the activation of Tie2 induces adhesion between vascular endothelial cells and vascular wall cells in a blood vessel to mature the blood vessel.
For example, in diseases where vascular wall cells observed in tumors, diabetic retinopathy, etc. do not adhere to vascular endothelial cells, disordered blood vessels grow, and by activating Tie2, vascular wall cells adhere to endothelial cells, It is known to normalize blood vessels.
For example, with respect to environmental factors that disrupt various intracellular and external vascular structures, activation of Tie2 is known to suppress vascular destabilization and stabilize blood vessels.
一方、Tie2の活性化により血管新生を抑制する天然由来の物質として、桂皮の抽出物が提案されている(例えば、特許文献1参照)。しかしながら、この提案では、活性が不十分であるという問題がある。また、血管新生を抑制する物質として、スラミンが知られているが(例えば、特許文献2参照)、安全性に優れないという問題がある。 On the other hand, an extract of cinnamon has been proposed as a naturally derived substance that suppresses angiogenesis through activation of Tie2 (see, for example, Patent Document 1). However, this proposal has a problem that the activity is insufficient. Moreover, although suramin is known as a substance which suppresses angiogenesis (for example, refer patent document 2), there exists a problem that it is not excellent in safety.
したがって、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用を有する安全性の高い物質について、速やかな開発が強く求められているのが現状である。 Accordingly, there is a strong demand for rapid development of highly safe substances having excellent Tie2 activation action, angiogenesis inhibition action, blood vessel maturation action, blood vessel normalization action, and blood vessel stabilization action. is the current situation.
本発明は、前記従来における諸問題を解決し、以下の目的を達成することを課題とする。即ち、本発明は、優れたTie2活性化作用を有し、安全性の高いTie2活性化剤を提供することを目的とする。
また、本発明は、優れた血管新生抑制作用を有し、安全性の高い血管新生抑制剤を提供することを目的とする。
また、本発明は、優れた血管の成熟化作用、血管の正常化作用又は血管の安定化作用を有し、安全性の高い血管の成熟化剤、血管の正常化剤又は血管の安定化剤を提供することを目的とする。
また、本発明は、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用の少なくともいずれかの作用を有し、安全性の高い医薬品組成物を提供することを目的とする。
An object of the present invention is to solve the conventional problems and achieve the following objects. That is, an object of the present invention is to provide a Tie2 activator having an excellent Tie2 activation action and high safety.
Another object of the present invention is to provide a highly safe angiogenesis inhibitor having an excellent angiogenesis inhibitory action.
In addition, the present invention has an excellent vascular maturation effect, vascular normalization effect or vascular stabilization effect, and is a highly safe vascular maturation agent, vascular normalization agent or vascular stabilization agent. The purpose is to provide.
In addition, the present invention has an excellent Tie2 activation action, angiogenesis inhibition action, vascular maturation action, vascular normalization action, and vascular stabilization action, and is highly safe. The object is to provide a pharmaceutical composition.
前記課題を解決するため本発明者が鋭意検討を重ねた結果、ツルレンゲ抽出物が、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用を有することを知見し、本発明を完成したものである。 As a result of intensive studies by the inventor in order to solve the above-mentioned problems, the Turrengue extract has an excellent Tie2 activation action, angiogenesis inhibition action, blood vessel maturation action, blood vessel normalization action, and blood vessel stabilization. The present invention has been completed by knowing that it has a crystallization effect.
本発明は、本発明者による前記知見に基づくものであり、前記課題を解決するための手段としては、以下の通りである。即ち、
<1> ツルレンゲ抽出物を有効成分として含有することを特徴とするTie2活性化剤である。
<2> ツルレンゲ抽出物を有効成分として含有することを特徴とする血管新生抑制剤である。
<3> ツルレンゲ抽出物を有効成分として含有することを特徴とする血管の成熟化剤、血管の正常化剤又は血管の安定化剤である。
<4> 前記<1>に記載のTie2活性化剤、前記<2>に記載の血管新生抑制剤、並びに前記<3>に記載の血管の成熟化剤、血管の正常化剤又は血管の安定化剤の少なくともいずれかを含有することを特徴とする医薬品組成物である。
This invention is based on the said knowledge by this inventor, and as a means for solving the said subject, it is as follows. That is,
<1> A Tie2 activator characterized by containing a vine extract as an active ingredient.
<2> An angiogenesis inhibitor characterized by containing a vine extract as an active ingredient.
<3> A vascular maturation agent, a vascular normalization agent, or a vascular stabilization agent characterized by containing a vine extract as an active ingredient.
<4> The Tie2 activator according to <1> above, the angiogenesis inhibitor according to <2> above, and the vascular maturation agent, blood vessel normalizing agent or blood vessel stability according to <3> above It is a pharmaceutical composition characterized by containing at least one of the agent.
本発明のTie2活性化剤によると、従来における前記諸問題を解決し、優れたTie2活性化作用を有し、安全性の高いTie2活性化剤を提供することができる。
本発明の血管新生抑制剤によると、従来における前記諸問題を解決し、優れた血管新生抑制作用を有し、安全性の高い血管新生抑制剤を提供することができる。
本発明の血管の成熟化剤、血管の正常化剤又は血管の安定化剤によると、従来における前記諸問題を解決し、優れた血管の成熟化作用、血管の正常化作用又は血管の安定化作用を有し、安全性の高い血管の成熟化剤、血管の正常化剤又は血管の安定化剤を提供することができる。
本発明の医薬品組成物によると、従来における前記諸問題を解決し、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用の少なくともいずれかの作用を有し、安全性の高い医薬品組成物を提供することができる。
According to the Tie2 activator of the present invention, it is possible to solve the conventional problems and to provide a highly safe Tie2 activator having an excellent Tie2 activation action.
According to the angiogenesis inhibitor of the present invention, the conventional problems can be solved, and an angiogenesis inhibitor having an excellent angiogenesis inhibitory action and high safety can be provided.
According to the blood vessel maturation agent, blood vessel normalization agent, or blood vessel stabilization agent of the present invention, the above-mentioned conventional problems are solved, and excellent blood vessel maturation action, blood vessel normalization action or blood vessel stabilization. It is possible to provide a highly safe vascular maturation agent, vascular normalization agent, or vascular stabilization agent that has an action.
According to the pharmaceutical composition of the present invention, the conventional problems are solved, and at least an excellent Tie2 activation action, angiogenesis inhibition action, blood vessel maturation action, blood vessel normalization action, and blood vessel stabilization action are provided. A pharmaceutical composition having any action and high safety can be provided.
(Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤)
本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤は、ツルレンゲ抽出物を有効成分として含有し、更に必要に応じてその他の成分を含有してなる。
(Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent)
The Tie2 activator, the angiogenesis inhibitor, the vascular maturation agent, the vascular normalization agent, and the vascular stabilization agent of the present invention contain a turrengue extract as an active ingredient, and if necessary, other Contains ingredients.
前記Tie2活性化剤は、Tie2をリン酸化することで、その活性体(リン酸化Tie2)に変換するTie2活性化作用を有する。前記Tie2の活性化により、細胞内チロシンキナーゼドメインの自己リン酸化が惹起され、血管内皮細胞と血管壁細胞との接着が誘導される。血管狭小化あるいは血管拡大化の抑制が原因となって生じる虚血性疾患では、Tie2の活性化により、血管腔が拡大化される。また、Tie2の活性化により、血管内皮細胞の細胞死を抑制することができる。 The Tie2 activator has a Tie2 activating action of phosphorylating Tie2 to convert it into its active form (phosphorylated Tie2). The activation of Tie2 causes autophosphorylation of the intracellular tyrosine kinase domain and induces adhesion between vascular endothelial cells and vascular wall cells. In an ischemic disease caused by suppression of vascular narrowing or vasodilation, the vascular cavity is enlarged by activation of Tie2. In addition, activation of Tie2 can suppress cell death of vascular endothelial cells.
前記血管新生抑制剤は、既存の血管から形成される新たな血管のネットワークを抑制する血管新生抑制作用を有する。低酸素状態では、Tie2の活性化が一時的に抑制され、血管内皮細胞と血管壁細胞との接着が乖離し、接着が乖離された血管内皮細胞から新しい血管のネットワークが形成される。前記血管新生抑制剤は、このような血管壁細胞が内皮細胞に接着しないことによる無秩序な血管の増生を抑制することができる。 The angiogenesis inhibitor has an angiogenesis inhibitory action that suppresses a network of new blood vessels formed from existing blood vessels. In the hypoxic state, the activation of Tie2 is temporarily suppressed, the adhesion between the vascular endothelial cell and the vascular wall cell is dissociated, and a new blood vessel network is formed from the vascular endothelial cell from which the adhesion is dissociated. The angiogenesis inhibitor can suppress the disordered growth of blood vessels caused by the adhesion of such vascular wall cells to endothelial cells.
前記血管の成熟化剤は、血管内皮細胞と血管壁細胞との接着を誘導して、血管内環境因子(細胞及び液性因子)が容易には血管外に漏出しないような血管内皮細胞間の接着斑を形成する成熟化作用を有する。また、血管再生医療においては、Tie2の活性化により、血管における血管内皮細胞と血管壁細胞との接着を誘導して、血管を成熟化させることができる。 The vascular maturation agent induces adhesion between vascular endothelial cells and vascular wall cells, and between vascular endothelial cells such that intravascular environmental factors (cells and humoral factors) do not easily leak out of the blood vessel. It has a maturation effect to form adhesion spots. Further, in vascular regenerative medicine, activation of Tie2 can induce adhesion between vascular endothelial cells and vascular wall cells in blood vessels, thereby allowing blood vessels to mature.
前記血管の正常化剤は、血管内皮細胞同士の接着を高めて血管壁細胞の血管内皮細胞への裏打ちを促進することにより、血管透過性の破綻した血管や無秩序な血管の増生を招くような異常な血管を、正常な状態にする正常化作用を有する。また、腫瘍、糖尿病性網膜症等で観察される血管壁細胞が血管内皮細胞に接着しないことにより無秩序な血管が増生する疾患では、Tie2の活性化により、血管壁細胞を内皮細胞に接着させ、血管を正常化させることができる。 The blood vessel normalizing agent promotes the lining of vascular wall cells to vascular endothelial cells by enhancing adhesion between vascular endothelial cells, thereby causing the growth of vascular permeability disrupted blood vessels and disordered blood vessels. It has a normalizing action to make abnormal blood vessels normal. In addition, in diseases where vascular wall cells observed in tumors, diabetic retinopathy, etc. do not adhere to vascular endothelial cells, diseased blood vessels grow, and by activating Tie2, vascular wall cells adhere to endothelial cells, It can normalize blood vessels.
前記血管の安定化剤は、既存の血管に対する障害、血管内皮細胞同士の解離、及び血管内皮細胞と血管壁細胞の解離を抑制して、血管内皮細胞の細胞死を抑制する血管の安定化作用を有する。また、種々の細胞内外の血管構造を破綻させる環境因子に対しては、Tie2の活性化により、血管の不安定化を抑制し、血管を安定化させることができる。 The blood vessel stabilizer suppresses cell death of vascular endothelial cells by suppressing damage to existing blood vessels, dissociation between vascular endothelial cells, and dissociation between vascular endothelial cells and vascular wall cells, Have In addition, with respect to environmental factors that break down various vascular structures inside and outside cells, activation of Tie2 can suppress vascular instability and stabilize blood vessels.
<ツルレンゲ抽出物>
前記ツルレンゲ(Astragalus complanatus R.Br.)は、マメ科ゲンゲ属の多年草の植物であり、ツルゲンゲとも呼ばれる。前記ツルレンゲは、中国の遼寧、吉林、河北、陜西、甘粛、山西、内モンゴル等の山野に生え、これらの地域から容易に入手可能である。前記ツルレンゲは、草丈が1m以上あり、全体が短い剛毛に覆われ、茎がやや扁平で地上をはうように生える。前記ツルレンゲの種子は、円みのある腎臓形で、沙苑子(シャエンシ)とも呼ばれ、肝機能や腎機能を補うなどの薬効があるとされている。
<Village extract>
The Astragalus complanatas R. Br. Is a perennial plant belonging to the genus Leguminosae, and is also referred to as a vine. The vines grow in mountain areas such as Liaoning, Jilin, Hebei, Shaanxi, Gansu, Shanxi, Inner Mongolia, etc. in China and are easily available from these areas. The vines have a plant height of 1 m or more, are covered with short bristles, and have stems that are slightly flat and grow on the ground. The seeds of vines are rounded kidneys, which are also referred to as shaenshi, and are said to have medicinal effects such as supplementing liver and kidney functions.
前記ツルレンゲの抽出物は、植物の抽出に一般に用いられる方法を利用することによって、容易に得ることができる。なお、前記ツルレンゲの抽出物には、ツルレンゲの抽出液、該抽出液の希釈液若しくは濃縮液、該抽出液の乾燥物、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。 The extract of vines can be easily obtained by using a method generally used for plant extraction. It should be noted that the extract of the vine genus includes an extract of vine jellyfish, a diluted or concentrated solution of the extract, a dried product of the extract, or a crudely purified product or a purified product thereof.
前記ツルレンゲの抽出部位としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、ツルレンゲの葉部、花部、茎部、果実、種子、根部などが挙げられる。これらの中でも、種子が好ましい。 There is no restriction | limiting in particular as an extraction site | part of the said vine rengue, According to the objective, it can select suitably, For example, a leaf part, a flower part, a stem part, a fruit, a seed, a root part, etc. are mentioned. Among these, seeds are preferable.
前記ツルレンゲの抽出部位の調製方法としては、各部位を乾燥させた後、そのまま又は粗砕機を用い粉砕して溶媒抽出に供することにより得ることができる。前記乾燥は、天日で行ってもよいし、通常使用されている乾燥機を用いて行ってもよい。 As a method for preparing the extraction site of the vine, it can be obtained by drying each site and then pulverizing it as it is or using a crusher and subjecting it to solvent extraction. The drying may be performed in the sun, or may be performed using a commonly used dryer.
前記ツルレンゲを抽出する方法としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、室温又は還流加熱下で、任意の抽出装置を用いて抽出する方法などが挙げられ、具体的には、抽出溶媒を満たした処理槽内に、抽出原料としてのツルレンゲを投入し、更に必要に応じて時々攪拌しながら、30分間〜2時間静置して可溶性成分を溶出した後、ろ過して固形物を除去し、得られた抽出液から抽出溶媒を留去し、乾燥することにより抽出する方法などが挙げられる。 The method for extracting the turrengue is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a method for extracting using any extraction device at room temperature or under reflux heating. Specifically, in the treatment tank filled with the extraction solvent, the turrengue as an extraction raw material is added, and further, with occasional stirring as necessary, it is allowed to stand for 30 minutes to 2 hours to elute soluble components, followed by filtration. Then, a method of extracting the solid by removing the solid solvent, distilling the extraction solvent from the obtained extract and drying it may be mentioned.
前記ツルレンゲの抽出に用いる溶媒としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、水、親水性有機溶媒、又はこれらの混合溶媒等を用いることができる。 There is no restriction | limiting in particular as a solvent used for the extraction of the said turrengue, According to the objective, it can select suitably, For example, water, a hydrophilic organic solvent, or these mixed solvents etc. can be used.
前記ツルレンゲの抽出溶媒として使用し得る水としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等の他、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、ろ過、イオン交換、浸透圧の調整、緩衝化等が含まれる。なお、前記抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。 The water that can be used as the extraction solvent for the vines is not particularly limited and can be appropriately selected according to the purpose. For example, pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, In addition to fresh water, etc., those subjected to various treatments are included. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. The water that can be used as the extraction solvent includes purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
前記ツルレンゲの抽出溶媒として使用し得る親水性有機溶媒としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数1〜5の低級アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数2〜5の多価アルコールなどが挙げられ、これら親水性有機溶媒と水との混合溶媒なども用いることができる。なお、前記水と前記親水性有機溶媒との混合溶媒を使用する際には、低級アルコールの場合は水10質量部に対して1質量部〜90質量部、低級脂肪族ケトンの場合は水10質量部に対して1質量部〜40質量部を混合したものを使用することが好ましい。また、多価アルコールの場合は水10質量部に対して1質量部〜90質量部を混合したものを使用することが好ましい。 There is no restriction | limiting in particular as a hydrophilic organic solvent which can be used as an extraction solvent of the said turrengue, According to the objective, it can select suitably, For example, C1-C5, such as methanol, ethanol, propyl alcohol, isopropyl alcohol, etc. Lower aliphatic ketones such as acetone and methyl ethyl ketone; polyhydric alcohols having 2 to 5 carbon atoms such as 1,3-butylene glycol, propylene glycol, and glycerin, and the like. A mixed solvent or the like can also be used. In addition, when using the mixed solvent of the said water and the said hydrophilic organic solvent, in the case of a lower alcohol, 1 mass part-90 mass parts with respect to 10 mass parts of water, and the water 10 in the case of a lower aliphatic ketone. It is preferable to use what mixed 1 mass part-40 mass parts with respect to the mass part. Moreover, in the case of polyhydric alcohol, it is preferable to use what mixed 1 mass part-90 mass parts with respect to 10 mass parts of water.
前記ツルレンゲの抽出条件としては、特に制限はなく、目的に応じて適宜選択することができるが、抽出溶媒量としては、抽出原料の5倍量〜15倍量(質量比)が好ましく、抽出溶媒として水を用いた場合には、50℃〜95℃で1時間〜4時間程度で抽出することが好ましく、抽出溶媒として水とエタノールとの混合溶媒を用いた場合には、40℃〜90℃で30分間〜4時間程度で抽出することが好ましい。 There are no particular limitations on the extraction conditions for the vine rengue, and it can be appropriately selected according to the purpose. The extraction solvent amount is preferably 5 to 15 times (mass ratio) the extraction raw material, and the extraction solvent When water is used, extraction is preferably performed at 50 ° C. to 95 ° C. for about 1 hour to 4 hours. When a mixed solvent of water and ethanol is used as an extraction solvent, 40 ° C. to 90 ° C. It is preferable to extract in about 30 minutes to 4 hours.
前記ツルレンゲ抽出物の精製方法としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、液−液分配抽出、各種クロマトグラフィー、膜分離などの精製方法が挙げられる。 There is no restriction | limiting in particular as a purification method of the said turlengue extract, According to the objective, it can select suitably, For example, purification methods, such as liquid-liquid partition extraction, various chromatography, and membrane separation, are mentioned.
前記ツルレンゲの抽出物は、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用を有しており、この作用に基づいて、本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤の有効成分として利用可能である。 The above-mentioned extract of turrengue has an excellent Tie2 activation action, angiogenesis inhibition action, blood vessel maturation action, blood vessel normalization action, and blood vessel stabilization action. It can be used as an active ingredient of the inventive Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent.
<その他の成分>
前記その他の成分としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、賦形剤、防湿剤、防腐剤、強化剤、増粘剤、乳化剤、酸化防止剤、甘味料、酸味料、調味料、着色料、香料等、美白剤、保湿剤、油性成分、紫外線吸収剤、界面活性剤、増粘剤、アルコール類、粉末成分、色剤、水性成分、水、皮膚栄養剤などが挙げられる。
また、前記その他の成分の具体例としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、ヒアルロン酸、ヒアルロン酸加水分解物、コラーゲン、コラーゲン加水分解物、アスコルビン酸、アスコルビン酸誘導体、アスコルビン酸配糖体、コエンザイムQ10、プロポリス、ローヤルゼリー、ローヤルゼリー蛋白分解物、フコイダン、アロエ粉末、アロエ抽出物、ブルーベリー粉末、ブルーベリー抽出物、イソフラボン、ノニ粉末、ノニ抽出物、ニンニク粉末、ニンニク抽出物、ウコン粉末、ウコン抽出物、キトサン、グルコサミン、クロレラ粉末、クロレラ抽出物、カルニチン、マカ粉末、マカ抽出物、カシス粉末、カシス抽出物、ハナビラタケ粉末、ハナビラタケ抽出物、その他美容に有効であるとされる植物の粉末及び/又は抽出物などが挙げられる。
<Other ingredients>
The other components are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include excipients, moisture-proofing agents, preservatives, reinforcing agents, thickeners, emulsifiers, antioxidants, and sweeteners. , Sour, seasoning, coloring, flavoring, whitening agent, moisturizer, oil component, UV absorber, surfactant, thickener, alcohol, powder component, colorant, aqueous component, water, skin nutrition Agents and the like.
Further, specific examples of the other components are not particularly limited and can be appropriately selected depending on the purpose. For example, hyaluronic acid, hyaluronic acid hydrolyzate, collagen, collagen hydrolyzate, ascorbic acid, ascorbine Acid derivatives, ascorbic acid glycosides, coenzyme Q10, propolis, royal jelly, royal jelly proteolysate, fucoidan, aloe powder, aloe extract, blueberry powder, blueberry extract, isoflavone, noni powder, noni extract, garlic powder, garlic Extract, turmeric powder, turmeric extract, chitosan, glucosamine, chlorella powder, chlorella extract, carnitine, maca powder, maca extract, cassis powder, cassis extract, hanabiratake powder, hanabiratake extract, and other beauty Plant powder Beauty / or extract and the like.
<用途>
本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤は、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用を有するため、腫瘍、慢性関節リウマチ、糖尿病網膜症、高脂血症、高血圧等の血管病変を主体とした疾患、アトピー性皮膚炎、及び花粉症などのアレルギー性疾患に関する医薬品、並びにこれらの疾患に関する安全な予防薬として好適に用いることができる。
また、本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤は、消化管で消化されるようなものでないことが確認されているため、美容用飲食品、健康用飲食品等の飲食品として、幅広く用いることができる。
<Application>
The Tie2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalizing agent, and blood vessel stabilizer of the present invention have excellent Tie2 activation action, angiogenesis inhibition action, and blood vessel maturation action. Since it has a blood vessel normalizing action and blood vessel stabilizing action, it is a disease mainly composed of vascular lesions such as tumor, rheumatoid arthritis, diabetic retinopathy, hyperlipidemia, hypertension, atopic dermatitis, and pollen. It can be suitably used as a pharmaceutical agent for allergic diseases such as infectious diseases and a safe preventive agent for these diseases.
In addition, it has been confirmed that the Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilizer of the present invention are not digested in the digestive tract. Therefore, it can be widely used as food and drink such as beauty food and drink and health food and drink.
本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤における前記ツルレンゲ抽出物の含有量としては、特に制限はなく、目的に応じて適宜選択することができ、前記ツルレンゲ抽出物そのものを本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤として用いてもよいが、Tie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤1mLあたり、1μg以上が好ましく、1μg以上が好ましく、10μg以上1,000μg以下がより好ましく、80μg以上820μg以下が更に好ましく、380μg以上820μg以下が特に好ましい。 There is no particular limitation on the content of the Tsurengage extract in the Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent of the present invention, depending on the purpose. The vine extract itself may be used as the Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent of the present invention. However, it is preferably 1 μg or more, preferably 1 μg or more, and preferably 10 μg or more and 1,000 μg or less per mL of Tie2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalizing agent, and blood vessel stabilizer. More preferably, it is 80 μg or more and 820 μg or less, more preferably 380 μg or more and 820 μg or less.
本発明のTie2活性化剤、血管の成熟化剤、血管の正常化剤、血管の安定化剤、及び血管新生抑制剤の投与形態としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、経口、非経口、外用などが挙げられる。 The administration form of the Tie2 activator, vascular maturation agent, vascular normalization agent, vascular stabilization agent, and angiogenesis inhibitor of the present invention is not particularly limited and should be appropriately selected according to the purpose. Examples thereof include oral, parenteral, and external use.
本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤の剤型としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、錠剤、粉剤、カプセル剤、顆粒剤、エキス剤、シロップ剤等の経口投与剤;注射剤、点滴剤、坐剤等の非経口投与剤;軟膏、クリーム、乳液、ローション、パック、及び浴用剤、頭髪化粧料等の外用剤などが挙げられる。 The dosage forms of the Tie2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalizing agent, and blood vessel stabilizer of the present invention are not particularly limited and should be appropriately selected according to the purpose. For example, tablets, powders, capsules, granules, extracts, syrups and other oral administration agents; injections, infusions, suppositories, and other parenteral administration agents; ointments, creams, emulsions, lotions, packs And external preparations such as bath preparations and hair cosmetics.
(医薬品組成物)
本発明の医薬品組成物は、上述した本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤の少なくともいずれかを含有し、更に必要に応じて医薬品に通常使用される添加剤を含有してもよい。
(Pharmaceutical composition)
The pharmaceutical composition of the present invention contains at least one of the above-described Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent of the present invention, You may contain the additive normally used for a pharmaceutical as needed.
本発明の医薬品組成物は、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用の少なくともいずれかの作用を有するため、腫瘍、慢性関節リウマチ、糖尿病網膜症、高脂血症、高血圧等の血管病変を主体とした疾患、アトピー性皮膚炎、及び花粉症などのアレルギー性疾患に関する医薬品、並びにこれらの疾患に関する安全な予防薬として好適に用いることができる。
また、本発明の医薬品組成物は、消化管で消化されるようなものでないことが確認されているため、美容用飲食品、健康用飲食品等の飲食品として、幅広く用いることができる。
Since the pharmaceutical composition of the present invention has at least one of the excellent Tie2 activation action, angiogenesis inhibition action, blood vessel maturation action, blood vessel normalization action, and blood vessel stabilization action, As a drug for allergic diseases such as rheumatoid arthritis, diabetic retinopathy, hyperlipidemia, hypertension and other vascular lesions, atopic dermatitis, and hay fever, and as a safe preventive drug for these diseases It can be used suitably.
Moreover, since it has been confirmed that the pharmaceutical composition of the present invention is not digested in the digestive tract, it can be widely used as a food or drink such as a beauty food or a health food.
本発明の医薬品組成物における前記ツルレンゲ抽出物の含有量としては、特に制限はなく、目的に応じて適宜選択することができ、前記ツルレンゲ抽出物そのものを本発明の医薬品組成物として用いてもよいが、医薬品組成物1mLあたり、1μg以上が好ましく、10μg以上1,000μg以下がより好ましく、80μg以上820μg以下が更に好ましく、380μg以上820μg以下が特に好ましい。 The content of the vine extract in the pharmaceutical composition of the present invention is not particularly limited and may be appropriately selected depending on the purpose. The vine extract itself may be used as the pharmaceutical composition of the present invention. However, it is preferably 1 μg or more, preferably 10 μg or more and 1,000 μg or less, more preferably 80 μg or more and 820 μg or less, and particularly preferably 380 μg or more and 820 μg or less per 1 mL of the pharmaceutical composition.
本発明の医薬品組成物の投与形態としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、経口、非経口、外用などが挙げられる。 There is no restriction | limiting in particular as an administration form of the pharmaceutical composition of this invention, According to the objective, it can select suitably, For example, oral, parenteral, external use, etc. are mentioned.
本発明の医薬品組成物の剤型としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、錠剤、粉剤、カプセル剤、顆粒剤、エキス剤、シロップ剤等の経口投与剤;注射剤、点滴剤、坐剤等の非経口投与剤;軟膏等の外用剤などが挙げられる。 There is no restriction | limiting in particular as a dosage form of the pharmaceutical composition of this invention, According to the objective, it can select suitably, For example, oral administration agents, such as a tablet, a powder agent, a capsule, a granule, an extract, a syrup agent, etc. ; Parenteral administration agents such as injections, instillations, suppositories; and external preparations such as ointments.
以下、本発明の実施例を説明するが、本発明は、これらの実施例に何ら限定されるものではない。 Examples of the present invention will be described below, but the present invention is not limited to these examples.
[試験例1:Tie2活性化作用(イムノアッセイ)試験]
(実施例1:ツルレンゲ抽出物)
コンフルエントまで培養した正常ヒト臍帯静脈内皮細胞(HUVEC)を、96ウェルプレートへ2.0×104細胞/0.1mL/ウェルとなるように播種し、低血清血管内皮細胞増殖用培地(倉敷紡績株式会社製、Humedia−EG2)を用いて一晩培養した。次に、一晩培養後の前記HUVECを、細胞刺激(被験試料添加)の3時間前に0.1mLの血管内皮細胞基礎培地(倉敷紡績株式会社製、Humedia−EB2)に置換し、再度培養を行った。その後、前記ウェル内に、被験試料として前記Humedia−EB2で表1に記載の濃度に調製したツルレンゲ抽出物(ツルレンゲ乾燥エキスF、丸善製薬株式会社製)を0.1mL添加し、10分間のインキュベーションを行った。インキュベーション後、イムノアッセイキット(R&D Systems社製、Human Phospho−Tie2(Y992)Immunoassay)を用いてプロトコールに従い、細胞内のリン酸化型Tie2量及び総Tie2量を測定し、総Tie2に対するリン酸化型Tie2の比率を計算した。
また、陰性コントロールとして用いたジメチルスルホキシド(DMSO)についても、同様に総Tie2に対するリン酸化型Tie2の比率を計算した。
Tie2活性化率は、下記式(1)を用いて計算した。そして、得られた活性化率をもとに、リン酸化作用を評価した。結果を表1に示す。
(Example 1: Turrengue extract)
Normal human umbilical vein endothelial cells (HUVEC) cultured to confluence were seeded in a 96-well plate at 2.0 × 10 4 cells / 0.1 mL / well, and a medium for low serum vascular endothelial cell proliferation (Kurashiki Spinning) The culture was carried out overnight using Humedia-EG2). Next, the HUVEC after overnight culture was replaced with 0.1 mL of vascular endothelial cell basal medium (Humdia-EB2 manufactured by Kurashiki Boseki Co., Ltd.) 3 hours before cell stimulation (addition of test sample) and cultured again. Went. Thereafter, 0.1 mL of a turrengue extract (Turengage dry extract F, manufactured by Maruzen Pharmaceutical Co., Ltd.) prepared as a test sample to the concentration shown in Table 1 was added to the well as a test sample, and incubated for 10 minutes. Went. After incubation, the amount of phosphorylated Tie2 and the total amount of Tie2 in the cells were measured according to the protocol using an immunoassay kit (manufactured by R & D Systems, Human Phospho-Tie2 (Y992) Immunoassay). The ratio was calculated.
For dimethyl sulfoxide (DMSO) used as a negative control, the ratio of phosphorylated Tie2 to total Tie2 was calculated in the same manner.
The Tie2 activation rate was calculated using the following formula (1). And phosphorylation action was evaluated based on the obtained activation rate. The results are shown in Table 1.
(参考例1:陽性コントロール)
実施例1において、前記ツルレンゲ抽出物を、陽性コントロールとしてAngiopoietin−1(R&D system社製)に変更し、表1に記載の濃度を用いた以外は、実施例9と同様にして、試験した。結果を表1に示す。
(Reference Example 1: Positive control)
In Example 1, the vine extract was changed to Angiopoietin-1 (manufactured by R & D system) as a positive control, and tested in the same manner as in Example 9, except that the concentrations shown in Table 1 were used. The results are shown in Table 1.
[試験例1:試験結果]
Tie2活性化作用(イムノアッセイ)の試験結果について説明する。
前記イムノアッセイキットによりTie2活性化作用の評価を実施したところ、ツルレンゲ抽出物により、Tie2がリン酸化して活性化されることが認められた。なお、陰性コントロールであるDMSOを添加した系では、Tie2の顕著なリン酸化は認められなかった。また、参考例1の陽性コントロールであるAngiopoietin−1を添加した系では、Tie2がリン酸化して活性化されることが認められた。ここで、Tie2のリン酸化により、血管成熟化、血管正常化、及び血管安定化がもたらされ、血管新生が抑制されることが知られている。
以上より、実施例で用いた抽出物が、Tie2リン酸化効果を有することにより、血管成熟化、血管正常化、及び血管安定化がもたらされ、血管新生が抑制されることが示唆された。
[Test Example 1: Test results]
The test result of Tie2 activation action (immunoassay) will be described.
When the Tie2 activation action was evaluated using the immunoassay kit, it was confirmed that Tie2 was phosphorylated and activated by the Turrengue extract. In the system to which DMSO as a negative control was added, no significant phosphorylation of Tie2 was observed. Moreover, in the system which added Angiopoietin-1 which is a positive control of Reference Example 1, it was confirmed that Tie2 was phosphorylated and activated. Here, it is known that phosphorylation of Tie2 leads to vascular maturation, vascular normalization, and vascular stabilization, and angiogenesis is suppressed.
From the above, it was suggested that the extracts used in the examples had Tie2 phosphorylation effects, which resulted in vascular maturation, vascular normalization, and vascular stabilization, and angiogenesis was suppressed.
本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物は、優れたTie2活性化作用、血管新生抑制作用、血管の成熟化作用、血管の正常化作用、及び血管の安定化作用の少なくともいずれかの作用を有するため、腫瘍、慢性関節リウマチ、糖尿病網膜症、高脂血症、高血圧などの血管病変を主体とした疾患に関する医薬品及びこれらの疾患に関する安全な予防薬として、幅広く用いることができる。
また、本発明のTie2活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物は、消化管で消化されるようなものでないことが確認されているため、美容用飲食品、健康用飲食品等の飲食品として、幅広く用いることができる。
The Tie2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalizing agent, blood vessel stabilizer, and pharmaceutical composition of the present invention have excellent Tie2 activation action, angiogenesis inhibition action, Mainly used for vascular lesions such as tumor, rheumatoid arthritis, diabetic retinopathy, hyperlipidemia, and hypertension because it has at least one of vascular maturation, vascular normalization, and vascular stabilization. It can be widely used as a pharmaceutical product relating to the above diseases and a safe preventive agent relating to these diseases.
Further, the Tie2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalizing agent, blood vessel stabilizer, and pharmaceutical composition of the present invention are not as digestible in the digestive tract. Therefore, it can be widely used as food and drink such as beauty food and drink and health food and drink.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012114785A JP6280685B2 (en) | 2012-05-18 | 2012-05-18 | Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012114785A JP6280685B2 (en) | 2012-05-18 | 2012-05-18 | Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013241355A true JP2013241355A (en) | 2013-12-05 |
JP6280685B2 JP6280685B2 (en) | 2018-02-14 |
Family
ID=49842652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012114785A Active JP6280685B2 (en) | 2012-05-18 | 2012-05-18 | Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6280685B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014097977A (en) * | 2012-10-17 | 2014-05-29 | Maruzen Pharmaceut Co Ltd | Tie2 ACTIVATOR, NEOVASCULARIZATION INHIBITOR, BLOOD VESSEL-MATURING AGENT, BLOOD VESSEL-NORMALIZING AGENT, BLOOD VESSEL STABILIZER, AND PHARMACEUTICAL COMPOSITION |
JP2015168656A (en) * | 2014-03-07 | 2015-09-28 | 丸善製薬株式会社 | Tie2 activator, neovascularization inhibitor, agent for blood vessel maturation, agent for blood vessel normalization, and blood vessel stabilizer, and pharmaceutical composition |
JP2015182966A (en) * | 2014-03-20 | 2015-10-22 | 日本メナード化粧品株式会社 | Proliferation promoting agents of hematopoietic stem cells and agents for maintaining undifferentiated state of hematopoietic stem cells |
JP2018111735A (en) * | 2018-04-24 | 2018-07-19 | 丸善製薬株式会社 | Tie 2 activator, angiogenesis inhibitor, vascular maturation agent, blood vessel normalization agent, and blood vessel stabilizer, and pharmaceutical composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005220100A (en) * | 2004-02-06 | 2005-08-18 | Maruzen Pharmaceut Co Ltd | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink |
JP2005320271A (en) * | 2004-05-07 | 2005-11-17 | Maruzen Pharmaceut Co Ltd | Aldose reductase activity inhibitor, diabetic complication-preventing/treating agent and diabetic complication-preventing/treating food and beverage |
JP2009107945A (en) * | 2007-10-26 | 2009-05-21 | Maruzen Pharmaceut Co Ltd | Inhibitor of optic nerve disorder and food and drink containing the same |
JP2010215536A (en) * | 2009-03-13 | 2010-09-30 | Maruzen Pharmaceut Co Ltd | Elastase activity-inhibiting agent |
JP2010215535A (en) * | 2009-03-13 | 2010-09-30 | Maruzen Pharmaceut Co Ltd | Melanin production-inhibiting agent |
-
2012
- 2012-05-18 JP JP2012114785A patent/JP6280685B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005220100A (en) * | 2004-02-06 | 2005-08-18 | Maruzen Pharmaceut Co Ltd | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink |
JP2005320271A (en) * | 2004-05-07 | 2005-11-17 | Maruzen Pharmaceut Co Ltd | Aldose reductase activity inhibitor, diabetic complication-preventing/treating agent and diabetic complication-preventing/treating food and beverage |
JP2009107945A (en) * | 2007-10-26 | 2009-05-21 | Maruzen Pharmaceut Co Ltd | Inhibitor of optic nerve disorder and food and drink containing the same |
JP2010215536A (en) * | 2009-03-13 | 2010-09-30 | Maruzen Pharmaceut Co Ltd | Elastase activity-inhibiting agent |
JP2010215535A (en) * | 2009-03-13 | 2010-09-30 | Maruzen Pharmaceut Co Ltd | Melanin production-inhibiting agent |
Non-Patent Citations (5)
Title |
---|
JPN6015052537; Hu YW, et al.: 'Induction of apoptosis in human hepatocarcinoma SMMC-7721 cells in vitro by flavonoids from Astragal' Journal of Ethnopharmacology Vol.123, No.2, 2009, p.293-301 * |
JPN6015052539; 堀越 朋子: '中医営養学と生活習慣病' 生活工学研究 第4巻,第1号, 2002, p.32-33 * |
JPN6015052541; Li JX, et al.: 'Antihypertensive effect of total flavonoid fraction of Astragalus complanatus in hypertensive rats' Chinese Journal of Physiology Vol.48, No.2, 2005, p.101-106 * |
JPN6015052543; Xue B, et al.: 'Effect of total flavonoid fraction of Astragalus complanatus R. Brown on angiotensin II-induced port' Phytomedicine Vol.15, No.9, 2008, p.759-762 * |
JPN6015052545; 高倉 伸幸: 'アンジオポエチンとTIE2受容体' 医学のあゆみ 第194巻,第10号, 20000902, p.736-741 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014097977A (en) * | 2012-10-17 | 2014-05-29 | Maruzen Pharmaceut Co Ltd | Tie2 ACTIVATOR, NEOVASCULARIZATION INHIBITOR, BLOOD VESSEL-MATURING AGENT, BLOOD VESSEL-NORMALIZING AGENT, BLOOD VESSEL STABILIZER, AND PHARMACEUTICAL COMPOSITION |
JP2015168656A (en) * | 2014-03-07 | 2015-09-28 | 丸善製薬株式会社 | Tie2 activator, neovascularization inhibitor, agent for blood vessel maturation, agent for blood vessel normalization, and blood vessel stabilizer, and pharmaceutical composition |
JP2015182966A (en) * | 2014-03-20 | 2015-10-22 | 日本メナード化粧品株式会社 | Proliferation promoting agents of hematopoietic stem cells and agents for maintaining undifferentiated state of hematopoietic stem cells |
JP2018111735A (en) * | 2018-04-24 | 2018-07-19 | 丸善製薬株式会社 | Tie 2 activator, angiogenesis inhibitor, vascular maturation agent, blood vessel normalization agent, and blood vessel stabilizer, and pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
JP6280685B2 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012073627A1 (en) | Tie2 ACTIVATOR, VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, ANTI-ANGIOGENIC AGENT, AGENT FOR MATURING BLOOD VESSELS, AGENT FOR NORMALIZING BLOOD VESSELS, AGENT FOR STABILIZING BLOOD VESSELS, AND PHARMACEUTICAL COMPOSITION | |
JP6444461B2 (en) | Tie2 activator, blood vessel maturation agent, blood vessel stabilizer, and food and drink for Tie2 activation | |
JP7429066B2 (en) | Tie2 activator, blood vessel maturation agent, blood vessel stabilizer, food and drink, and external preparation | |
JP6280685B2 (en) | Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent | |
JP2011016760A (en) | Skin care external preparation, oral agent, moisturizing agent, anti-aging agent, bleaching agent, and anti-oxidizing agent containing bulb of lilium plant and/or callus extract as effective ingredient | |
JP6293402B2 (en) | Tie2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalizing agent, and food and drink | |
JP6452552B2 (en) | Tie2 activator, vascular maturation agent, vascular stabilizer, lymphatic vessel stabilizer, and oral composition for activating Tie2 | |
JP6346761B2 (en) | Tie2 activator, pharmaceutical composition, and oral composition | |
JP2018140950A (en) | Tie 2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalization agent, blood vessel stabilizer, pharmaceutical composition, composition for food and beverage, and food and drink | |
JP6969041B2 (en) | Vascular Endothelial Nitric Oxide Synthetic Enzyme Production Promoter and Oral Composition | |
JP6736645B2 (en) | Claudin-5 production promoter and oral composition for promoting claudin-5 production | |
JP5859180B2 (en) | TNF-α production inhibitor, cyclic AMP phosphodiesterase inhibitor, cyclooxygenase-2 (COX-2) inhibitor, elastase activity inhibitor, estrogen-like agent, type I collagen production promoter, and type IV collagen production promoter | |
JP6272012B2 (en) | Dendritic negative regulator | |
JP2022124930A (en) | External preparation for skin, wrinkle improver, and collagen production promoter | |
KR20170025369A (en) | Composition for improving skin | |
JP2011001327A (en) | INHIBITOR ON INCREASE IN STEM CELL PROLIFERATION FACTOR mRNA EXPRESSION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160304 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161124 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170104 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170316 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6280685 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |